510(k) device
VITROS Immunodiagnostic Products NT-proBNP II Reagent Pack
Ortho Clinical Diagnostics · Test, Natriuretic Peptide (NBC, Class II) · First FDA decision Jun 6, 2006, newest Oct 4, 2021Heart attack and heart failure blood testsHeart failure
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
0
Naming "VITROS Immunodiagnostic Products"
MAUDE reports
2,398
Brand "VITROS Immunodiagnostic Products", since 2015
PubMed studies
13
Mentioning "VITROS Immunodiagnostic Products"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing VITROS Immunodiagnostic Products NT-proBNP II Reagent Pack
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K201312 · Decided Oct 4, 2021 · 504 days after receipt
Device type: Test, Natriuretic Peptide (NBC) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- B-type Natriuretic Peptide (BNP) TestingLocal determinationIn effectL33573Wellpoint FederalUpdated Jul 14, 2026
- B-type Natriuretic Peptide (BNP) TestingLocal determinationIn effectL35526Noridian Healthcare Solutions, LLCUpdated Feb 23, 2026
- B-type Natriuretic Peptide (BNP) TestingLocal determinationIn effectL34410Palmetto GBAUpdated Dec 22, 2025
- B-type Natriuretic Peptide (BNP) TestingLocal determinationIn effectL33943CGS Administrators, LLCUpdated Nov 26, 2025
- B-type Natriuretic Peptide (BNP) TestingProposed local determinationProposedDL34410Palmetto GBAUpdated Jan 31, 2025
- B-Type Natriuretic Peptide (BNP)Local determinationIn effectL33267First Coast Service Options, Inc.Updated Nov 21, 2019
Clinical trials
Device studies on ClinicalTrials.gov that name "VITROS Immunodiagnostic Products", any status and sponsor, newest update first.
No registered device study names "VITROS Immunodiagnostic Products".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "VITROS Immunodiagnostic Products", and for the whole product code for context.
This brand
2,398 reports: 2,388 malfunction, 10 injury, 0 death
Whole product code NBC
183 reports: 178 malfunction, 5 injury, 0 death
Newest reports for this brand
Ortho-Clinical Diagnostics, Inc.
3007111389-2026-00163 · Received Oct 16, 2026 · Event dated Sep 17, 2026
Device type: General Purpose Reagent (PPM)
Device problem as coded: Low Test Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0689-2019 · Started Nov 1, 2018
Reason given: The firm is extending their previous July 2018 recall to include additional product codes. Biased results may occur for these additional products at biotin concentrations which are lower than indicated in the current Instructions for Use.
Cause as FDA categorized it: Device Design · Device type: Test, Natriuretic Peptide (NBC)
1 more recall records with a free account
Published research
The most relevant PubMed records for "VITROS Immunodiagnostic Products"[tiab]. The summary above synthesizes these.
- Analytical performance of the VITROS® Immunodiagnostic Products total PSA II and free PSA assays.
De Keukeleire S, Wauters A, Luyts D, et al. · Clin Biochem · 2014Comparative Study, Research Support, Non-U.S. Gov't
- Clinical Performance of an N-Terminal Pro-B-Type Natriuretic Peptide Assay in Acute Heart Failure Diagnosis.
Daniels LB, Ajongwen P, Christenson RH, et al. · J Appl Lab Med · 2025Multicenter Study
- Examination of SARS-CoV-2 serological test results from multiple commercial and laboratory platforms with an in-house serum panel.
Lester SN, Stumpf M, Freeman BD, et al. · Access Microbiol · 2024
- Technical and clinical evaluation of the VITROS® Immunodiagnostic Products 25-OH Vitamin D Total Assay--comparison with marketed automated immunoassays and a liquid chromatography-tandem mass spectrometry method.
Cavalier E, Rousselle O, Ferrante N, et al. · Clin Chem Lab Med · 2013Comparative Study, Research Support, Non-U.S. Gov't
- Clinical evaluation of four commercial immunoassays for the detection of antibodies against established SARS-CoV-2 infection.
Chua KYL, Vogrin S, Bittar I, et al. · Pathology · 2020Comparative Study
- Bimodal distributions of anti-Trypanosoma cruzi antibody levels in blood donors are associated with parasite detection and antibody waning in peripheral blood.
Remesar MC, Sabino EC, Buss LF, et al. · PLoS Negl Trop Dis · 2025Research Support, N.I.H., Extramural
- Declining antibody levels to Trypanosoma cruzi correlate with polymerase chain reaction positivity and electrocardiographic changes in a retrospective cohort of untreated Brazilian blood donors.
Buss LF, Campos de Oliveira-da Silva L, Moreira CHV, et al. · PLoS Negl Trop Dis · 2020Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Is Sunshine Vitamin Related to Adolescent Depression? A Cross-Sectional Study of Vitamin D Status and Depression Among Rural Adolescents.
Tarikere Satyanarayana P, Suryanarayana R, Theophilus Yesupatham S, et al. · Cureus · 2023
- Clinical and Analytical Performance Evaluation of an Automated Procalcitonin Assay.
Ogbonna G, Atienza JR, Singleton DW, et al. · J Appl Lab Med · 2025Evaluation Study
- Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis.
Ammitzbøll C, Bartels LE, Bøgh Andersen J, et al. · ACR Open Rheumatol · 2021
- Clinical Use of a New High-Sensitivity Cardiac Troponin I Assay in Patients with Suspected Myocardial Infarction.
Boeddinghaus J, Twerenbold R, Nestelberger T, et al. · Clin Chem · 2019Multicenter Study, Observational Study
- 0/2ߙh-Algorithm for Rapid Triage of Suspected Myocardial Infarction Using a Novel High-Sensitivity Cardiac Troponin I Assay.
Wildi K, Boeddinghaus J, Nestelberger T, et al. · Clin Chem · 2022
Other devices of this type
Also filed under product code NBC.
- Elecsys proBNP II, Elecsys proBNP II STATRoche Diagnostics · 510(k) 2023
- Triage Bnp Test for Beckman Coulter Immunoassay Systems, Model 98200Biosite Incorporated · 510(k) 2006
- Elecsys Probnp ImmunoassayRoche Diagnostics Corp. · 510(k) 2005
- Triage B-Type Natriuretic Peptide (Bnp) TestBiosite Incorporated · De Novo 2002
- Access BNP IIBeckman Coulter, Inc. · 510(k) 2026
- Access NT-proBNPBeckman Coulter, Inc. · 510(k) 2026
- Alere NT-proBNP for Alinity iAxis-Shield Diagnostics, Ltd. · 510(k) 2026
- Stratus Cs Acute Care Nt-Probnp Testpak, Model CpbnpmDade Behring, Inc. · 510(k) 2007
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.